Senseonics (NYSE:SENS) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Senseonics (NYSE:SENS) in a research note issued to investors on Tuesday. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $2.00 price target on shares of Senseonics in a research report on Friday, November 15th.

Senseonics Trading Up 19.6 %

Shares of Senseonics stock opened at $0.43 on Tuesday. The firm has a market capitalization of $256.76 million, a PE ratio of -3.32 and a beta of 0.77. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. The company’s fifty day moving average price is $0.33 and its two-hundred day moving average price is $0.38. Senseonics has a 52-week low of $0.25 and a 52-week high of $0.75.

Insider Activity

In other Senseonics news, CFO Frederick T. Sullivan purchased 124,933 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $0.38 per share, with a total value of $47,474.54. Following the purchase, the chief financial officer now directly owns 2,478,844 shares of the company’s stock, valued at $941,960.72. The trade was a 5.31 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Timothy T. Goodnow purchased 315,000 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The shares were acquired at an average cost of $0.31 per share, with a total value of $97,650.00. Following the completion of the purchase, the chief executive officer now directly owns 11,310,355 shares in the company, valued at approximately $3,506,210.05. This represents a 2.86 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC increased its position in shares of Senseonics by 48,267.2% in the third quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after purchasing an additional 167,970 shares during the period. GSA Capital Partners LLP acquired a new stake in Senseonics in the third quarter valued at about $117,000. Symmetry Partners LLC acquired a new stake in Senseonics in the third quarter valued at about $164,000. Cubist Systematic Strategies LLC boosted its stake in Senseonics by 25.9% in the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after buying an additional 85,501 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in Senseonics by 16.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after buying an additional 51,000 shares in the last quarter. Institutional investors and hedge funds own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.